Article
Pharmacology & Pharmacy
Kjell-Erik Arnesen, Ann Vinh Phung, Karoline Randsborg, Irene Mork, Marlene Thorvall, Gisle Langslet, Arne Svilaas, Cecilie Wium, Leiv Ose, Kjetil Retterstol
Summary: The study aimed to investigate the long-term treatment effects of intensive lipid lowering medication and optimized lifestyle in patients with familial hypercholesterolemia. Results showed that under intensive treatment, the average LDL-C in FH patients was reduced to 3.0 mmol/L, with women having higher LDL-C levels than men. The majority of patients with established ASCVD at enrollment experienced new events during the study period, while FH patients in primary prevention had a low cardiovascular risk of 13% in ten years.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Medicine, General & Internal
Shengjun Xiong, Shizhang Yin, Wanshu Deng, Yuanhui Zhao, Wenhang Li, Pengbo Wang, Zhao Li, Hongmei Yang, Ying Zhou, Shasha Yu, Xiaofan Guo, Yingxian Sun
Summary: This study demonstrates that ACEF scores are associated with CVD in the general population and can be used to identify high-risk patients.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Rheumatology
Tsai-Hung Yen, Yun-Wen Chen, Tsu-Yi Hsieh, Yi-Ming Chen, Wen-Nan Huang, Yi-Hsing Chen, Hsin-Hua Chen
Summary: This study aimed to assess the incidence and risk factors of major adverse cardiovascular events (MACEs) in patients with systemic sclerosis (SSc). A nationwide cohort study was conducted in Taiwan, including 1379 SSc patients and 2758 non-SSc individuals. The study found that SSc was associated with increased risk of myocardial infarction and peripheral arterial occlusion disease, but not of ischaemic stroke. Age, gender, residential area, valvular heart disease, rheumatoid arthritis, and the use of clopidogrel and aspirin were identified as independent risk factors for MACEs in SSc patients. The findings of this study are clinically significant in understanding the risk factors for MACEs in SSc patients.
Article
Rheumatology
Netanja Harlianto, Nadine Oosterhof, Wouter Foppen, Marjolein E. Hol, Rianne Wittenberg, Pieternella H. van der Veen, Bram van Ginneken, Firdaus A. A. Mohamed Hoesein, Jorrit-Jan Verlaan, Pim A. de Jong, Jan Westerink
Summary: This study found that the presence of DISH is independently associated with an increased incidence and risk for ischemic stroke, but not with other cardiovascular events and all-cause mortality.
Article
Critical Care Medicine
Daniel D. Fraughen, Auyon J. Ghosh, Brian D. Hobbs, Georg-Christian Funk, Tobias Meischl, Christian F. Clarenbach, Noriane A. Sievi, Karin Schmid-Scherzer, Oliver J. McElvaney, Mark P. Murphy, Adam D. Roche, Louise Clarke, Matthew Strand, Florian Vafai-Tabrizi, Geraldine Kelly, Cedric Gunaratnam, Tomas P. Carroll, Noel G. McElvaney
Summary: This real-world study demonstrates the survival advantage of IV-AAT in severe AATD patients. This improved survival is not related to the decline in lung function FEV1. Patients are divided into two major phenotypes, lung indexes and non-lung indexes, which have implications for clinical trial design, especially when FEV1 is the primary endpoint.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Jaewon Shin, Jong-Won Chung, Hyun-Soon Jang, Juneyoung Lee, Keun-Sik Hong, Oh Young Bang, Gyeong-Moon Kim, Woo-Keun Seo
Summary: Lowering low-density lipoprotein cholesterol levels can significantly reduce the risk of stroke, with no significant increase in the risk of hemorrhagic stroke at very low levels.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Raffaele Marfella, Francesco Prattichizzo, Celestino Sardu, Pasquale Paolisso, Nunzia D'Onofrio, Lucia Scisciola, Rosalba La Grotta, Chiara Frige, Franca Ferraraccio, Iacopo Panarese, Mara Fanelli, Piero Modugno, Antonio Maria Calafiore, Mario Melchionna, Ferdinando Carlo Sasso, Fulvio Furbattoj, Davide D'Andreaj, Mario Siniscalchi, Ciro Mauro, Arturo Cesaro, Paolo Calabro, Gaetano Santulli, Maria Luisa Balestrieri, Emanuele Barbato, Antonio Ceriello, Giuseppe Paolisso
Summary: This study found that PCSK9 inhibitors, used as monotherapy, can reduce the expression of inflammatory markers within atherosclerotic plaques and increase the abundance of SIRT3 and collagen. Patients treated with PCSK9 inhibitors had a decreased risk of cardiovascular events. Additionally, the expression of PCSK9 was positively correlated with the expression of pro-inflammatory proteins within the plaque, and the inflammatory burden was associated with an increased risk of cardiovascular events.
Article
Medicine, General & Internal
Chentang Wu, Xueyun Chen
Summary: Elevated serum NEFA levels were found to be associated with a higher risk of cardiovascular events in CKD patients, potentially serving as a new predictor for such events.
INTERNATIONAL JOURNAL OF GENERAL MEDICINE
(2021)
Article
Endocrinology & Metabolism
Tali Cukierman-Yaffe, Hertzel C. Gerstein, Jan Basile, M. Angelyn Bethel, Ernesto G. Cardona-Munoz, Ignacio Conget, Gilles Dagenais, Edward Franek, Stephanie Hall, Nicolae Hancu, Petr Jansky, Mark Lakshmanan, Fernando Lanas, Lawrence A. Leiter, Patricio Lopez-Jaramillo, Valdis Pirags, Nana Pogosova, Jeffrey Probstfield, Purnima Rao-Melacini, Chinthanie Ramasundarahettige, Peter J. Raubenheimer, Matthew C. Riddle, Lars Ryden, Jonathan E. Shaw, Wayne H-H Sheu, Theodora Temelkova-Kurktschiev
Summary: This study investigates the relationship between cognitive scores and cardiovascular outcomes, finding that low cognitive scores are risk factors for adverse cardiovascular events. The use of novel cognitive indices can strengthen this relationship.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Medicine, General & Internal
Christopher P. Long, Alison X. Chan, Christine Y. Bakhoum, Christopher B. Toomey, Samantha Madala, Anupam K. Garg, William R. Freeman, Michael H. Goldbaum, Anthony N. DeMaria, Mathieu F. Bakhoum
Summary: The study investigated the potential of retinal ischemic perivascular lesions (RIPLs) as a biomarker for cardiovascular disease by analyzing RIPLs in patients with documented cardiovascular disease and healthy controls. The presence of RIPLs, which are anatomical markers of prior retinal ischemic infarcts, was associated with higher odds of cardiovascular disease and may serve as an additional biomarker for identifying patients at risk of adverse cardiovascular events.
Article
Pharmacology & Pharmacy
Sharon Attipoe-Dorcoo, Peter Yang, Laurence Sperling, Fleetwood Loustalot, Angela M. Thompson-Paul, Elizabeth B. Gray, Soyoun Park, Matthew D. Ritchey
Summary: The study found that the prescription fills of PCSK9 inhibitors have significantly increased nationwide since 2015, with prices decreasing and the number of new users continuously rising. This suggests further support for the use of PCSK9 inhibitors in lowering LDL-C levels and reducing cardiovascular events.
JOURNAL OF CLINICAL LIPIDOLOGY
(2021)
Article
Oncology
Benjamin Lowentritt, Dominic Pilon, Dexter Waters, Carmine Rossi, Erik Muser, Siyana Kurteva, Aditi Shah, Ibrahim Khilfeh, Shawn Du, Lorie Ellis, Patrick Lefebvre, Gordon Brown
Summary: This study compared the prostate-specific antigen response (PSA90) between patients with metastatic castration-sensitive prostate cancer (mCSPC) who were treated with apalutamide or abiraterone acetate. The results showed that patients treated with apalutamide were more likely to achieve a PSA90 reduction within 6 months compared to those treated with abiraterone acetate.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2023)
Article
Cardiac & Cardiovascular Systems
Ruifeng Liu, Xiangyu Gao, Siwen Liang, Huiqiang Zhao
Summary: This study aimed to determine the prognosis of patients with coronary artery ectasia (CAE). The results showed that the prognosis of patients with CAE and comorbid acute myocardial infarction (AMI) was worse than those with AMI alone, and the overall prognosis of patients with CAE was worse than those with coronary heart disease (CHD). The CAE + AMI and CAE groups had different characteristics, with the former being prone to AMI reoccurrence and the latter being prone to repeated angina pectoris.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Review
Immunology
Jiuyang Xu, Yaqun Teng, Lianhan Shang, Xiaoying Gu, Guohui Fan, Yijun Chen, Ran Tian, Shuyang Zhang, Bin Cao
Summary: The study found no association between prior use of ACEI/ARB and the risk of COVID-19 infection, and using ACEI/ARB did not change the severity of the disease among patients. This suggests that the current medical guidelines and position statements supporting the continuation of ACEI/ARB use are evidence-based and appropriate.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Genetics & Heredity
Angela L. Duker, Dagmar Kinderman, Christy Jordan, Tim Niiler, Carissa M. Baker-Smith, Louise Thompson, David A. Parry, Ricki S. Carroll, Michael B. Bober
Summary: Patients with MOPDII exhibit systemic vascular pathologies and various comorbidities, diagnosed at a young age, requiring close monitoring of blood pressure, and consideration for cardiac and renal vascular screenings.
ORPHANET JOURNAL OF RARE DISEASES
(2021)
